Discover 644 paid clinical trials in Charlotte, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Charlotte offers many opportunities to participate in clinical research focused on various conditions, including cancer, lymphoma, heart disease, and cystic fibrosis. The city’s medical research institutions are recruiting both healthy volunteers interested in paid trials, as well as individuals with specific health conditions.
Filter
2
Filter results
Results: 644
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Charlotte NC, Goldsboro NC, Charlottesville VA,
Location: Charlotte NC, Washington DC, Edison NJ, West Orange NJ,
Sponsor: BrainQ Technologies Ltd.
Sex: All
Age: 22 - 70+
Code: NCT06386874
Recruiting
Physical Therapy Wound Care Modalities in Patients With Spinal Cord Injury (SCI)
for
Spinal Cord Injuries, Pressure Injuries
Location: Charlotte NC
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 18+
Code: NCT05458947
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
for
Chickenpox
Location: Charlotte NC, Simpsonville SC, Greenville SC,
Sponsor: GlaxoSmithKline
Sex: All
Age: 1
Code: NCT06740630
Phase3, Recruiting
New
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
for
Renal Insufficiency, Chronic
Location: Charlotte NC, Savannah GA, Louisville KY, Riverview FL,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT07624305
Phase3, Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Charlotte NC, Winston-Salem NC, Norfolk VA, Fairfax VA,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06129864
Phase3, Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
for
Relapsed/Refractory Multiple Myeloma
Location: Charlotte NC, Durham NC, Atlanta GA, Charlottesville VA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05850234
Phase1, Phase2, Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
for
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma,
Location: Charlotte NC, Columbus OH, Pittsburgh PA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06564038
Phase1, Phase2, Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
for
Major Depressive Disorder
Location: Charlotte NC, Atlanta GA, Savannah GA, Marietta GA,
Sponsor: Xenon Pharmaceuticals Inc.
Sex: All
Age: 18 - 70+
Code: NCT06775379
Phase3, Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
for
B-cell Malignancies
Location: Charlotte NC, Winston-Salem NC, New York NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06542250
Phase1, Phase2, Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
for
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer,
Location: Charlotte NC, Pittsburgh PA, Baltimore MD, Commack NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05123482
Phase1, Phase2, Recruiting
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
for
Chronic Lymphocytic Leukemia (CLL),
Location: Charlotte NC, Winston-Salem NC, Durham NC, Boston MA
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT07024706
Phase2, Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2